海普瑞(09989.HK)2021年收入增長19.6%至63.6億元
格隆匯4月11日丨海普瑞(09989.HK)公吿,截至2021年12月31日止年度經審核全年業績,收入增長19.6%至人民幣63.6億元;製劑業務銷售收入增長74.6%至人民幣26.38億元;CDMO業務收入增長2.0%至人民幣8.13億元;其中賽灣生物收入增長17.3%至人民幣6.93億元。
剔除對外投資相關項目對集團利潤表的税後影響值(包括投資收益、公允價值變動收益、投資項目相關資產減值等),以及税後結構性匯兑損益,2021年歸屬於母公司持有者應占基本盈利約人民幣5.57億元。董事會建議宣派2021年度的末期現金股息每10股普通股人民幣0.35元(含税)。
集團在製劑業務、依諾肝素API及賽灣生物板塊均取得亮眼的成績,收入增長強勁。這一方面反映了管理層近年採取的以核心業務向製劑轉型所帶來的效益,另一方面亦展現了集團堅韌的抗逆能力。
自2016年出海伊始至今,集團的製劑國際業務已遍佈全球,五年內銷售逾40個地區及市場,並在英國、波蘭、意大利等多個市場份額名列前茅,取得了顯著成績。報吿期內,集團的製劑業務總銷售量超過1.8億支,同比增長72.6%。
2021年,集團再一次於歐洲市場取得亮麗的成績。報吿期內,銷售量較去年同比上升49.3%,收入同比增長59.3%。
2022年將是集團業務板塊提升和盈利能力改善的起點,公司將呈現出與2021年截然不同的面貌。未來一年,集團收入將保持穩健和具持續性的增長,更重要的是,集團將改善財務表現及盈利能力,推動企業價值的不斷提升,公司充滿信心能夠達到目標。
集團會持續鞏固肝素產業鏈業務的核心優勢及行業領先地位,保持收入較快速的增長。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.